Upadacitinib and secukinumab for PsA offers comparable improvements in skin and joint symptoms, but adalimumab offers superior pain relief.
OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal PainLONDON and NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback